Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, 3, IV, and V hyperlipoproteinemia. Studies in 26 patients and 5 normal persons.
D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D001796:Blood Protein Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D004032:Diet; D004562:Electrocardiography; D004586:Electrophoresis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D006867:Hydrolases / Q000097:blood; D006949:Hyperlipidemias / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008049:Lipase / Q000097:blood; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D009640:Norethindrone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D010195:Pancreatitis / Q000150:complications; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood*
D000085:Acetates; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D007328:Insulin; D008074:Lipoproteins; D014280:Triglycerides; D006493:Heparin; D006867:Hydrolases; D008049:Lipase; D009640:Norethindrone